Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...

In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...

Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...

Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...

The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

New survey data show a strong patient preference for fully remote clinical trials, underscoring how convenience, intuitive technology, and FDA-cleared digital tools are reshaping enrollment and ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...